Search PepX: ubl conjugation
48 results
Results
| PDB Identifier | Description | Ligand | Receptor | SCOP | pdb.org | |
|---|---|---|---|---|---|---|
  |
2J6F | N-TERMINAL SH3 DOMAIN OF CMS (CD2AP HUMAN HOMOLOG) BOUND TO CBL-B PEPTIDE | C | A |
 |
|
  |
2JCC | AH3 RECOGNITION OF MUTANT HLA-A2 W167A | C | EFA | Immunoglobulin-like beta-sandwich |
|
  |
2QPY | AR LBD with small molecule | B | A | Nuclear receptor ligand-binding domain |
|
  |
2R28 | The complex Structure of Calmodulin Bound to a Calcineurin Peptide | C | AB | EF Hand-like |
|
  |
2RFX | Crystal Structure of HLA-B*5701, presenting the self peptide, LSSPVTKSF | C | A | MHC antigen-recognition domain |
|
  |
2UWE | LARGE CDR3A LOOP ALTERATION AS A FUNCTION OF MHC MUTATION | C | EFA | Immunoglobulin-like beta-sandwich |
|
  |
2V2W | T CELL CROSS-REACTIVITY AND CONFORMATIONAL CHANGES DURING TCR ENGAGEMENT | C | A | MHC antigen-recognition domain |
|
  |
2V2X | T CELL CROSS-REACTIVITY AND CONFORMATIONAL CHANGES DURING TCR ENGAGEMENT. | C | A | MHC antigen-recognition domain |
|
  |
2VAY | CALMODULIN COMPLEXED WITH CAV1.1 IQ PEPTIDE | B | A | EF Hand-like |
|
  |
2VLJ | THE STRUCTURAL DYNAMICS AND ENERGETICS OF AN IMMUNODOMINANT T-CELL RECEPTOR ARE PROGRAMMED BY ITS VBETA DOMAIN | C | DEA | Immunoglobulin-like beta-sandwich |
|
  |
2VLK | THE STRUCTURAL DYNAMICS AND ENERGETICS OF AN IMMUNODOMINANT T-CELL RECEPTOR ARE PROGRAMMED BY ITS VBETA DOMAIN | C | DEA | Immunoglobulin-like beta-sandwich |
|
  |
2VLL | THE STRUCTURAL DYNAMICS AND ENERGETICS OF AN IMMUNODOMINANT T-CELL RECEPTOR ARE PROGRAMMED BY ITS VBETA DOMAIN | C | A | MHC antigen-recognition domain |
|
  |
2VLR | THE STRUCTURAL DYNAMICS AND ENERGETICS OF AN IMMUNODOMINANT T-CELL RECEPTOR ARE PROGRAMMED BY ITS VBETA DOMAIN | C | DEA | Immunoglobulin-like beta-sandwich |
|
  |
2W73 | HIGH-RESOLUTION STRUCTURE OF THE COMPLEX BETWEEN CALMODULIN AND A PEPTIDE FROM CALCINEURIN A | K | ABF |
|
|
  |
2Z32 | Crystal structure of Keap1 complexed with Prothymosin alpha | B | A | 6-bladed beta-propeller |
|
  |
3BEJ | Structure of human FXR in complex with MFA-1 and co-activator peptide | E | A | Nuclear receptor ligand-binding domain |
|
  |
3BO8 | The High Resolution Crystal Structure of HLA-A1 Complexed with the MAGE-A1 Peptide | C | A |
|
|
  |
3BP4 | The high resolution crystal structure of HLA-B*2705 in complex with a Cathepsin A signal sequence peptide pCatA | C | A |
|
|
  |
3BP7 | The high resolution crystal structure of HLA-B*2709 in complex with a Cathepsin A signal sequence peptide, pCatA | C | A |
|
|
  |
3BQD | Doubling the Size of the Glucocorticoid Receptor Ligand Binding Pocket by Deacylcortivazol | B | A | Nuclear receptor ligand-binding domain |
|
  |
3BW9 | Crystal Structure of HLA B*3508 in complex with a HCMV 12-mer peptide from the pp65 protein | C | A | MHC antigen-recognition domain |
|
  |
3BWA | Crystal Structure of HLA B*3508 in complex with a HCMV 8-mer peptide from the pp65 protein | C | A | MHC antigen-recognition domain |
|
  |
3BXL | Crystal structure of the R-type calcium channeL (CaV2.3) IQ domain and CA2+calmodulin complex | B | A | EF Hand-like |
|
  |
3BYA | Structure of a Calmodulin Complex | B | A |
|
|
  |
3BZF | The human non-classical major histocompatibility complex molecule HLA-E | P | A | MHC antigen-recognition domain |
|
  |
3C9N | Crystal Structure of a SARS Corona Virus Derived Peptide Bound to the Human Major Histocompatibility Complex Class I molecule HLA-B*1501 | C | A | MHC antigen-recognition domain |
|
  |
3D18 | Crystal structure of HLA-B*2709 complexed with a variant of the latent membrane protein 2 peptide (LMP2(L)) of epstein-barr virus | C | A |
|
|
  |
3D7V | Crystal structure of Mcl-1 in complex with an Mcl-1 selective BH3 ligand | B | A |
|
|
  |
3DCG | Crystal Structure of the HIV Vif BC-box in Complex with Human ElonginB and ElonginC | F | B | POZ domain |
|
  |
3DCT | FXR with SRC1 and GW4064 | B | A | Nuclear receptor ligand-binding domain |
|
  |
3DX6 | Crystal Structure of B*4402 presenting a 10mer EBV epitope | C | A |
|
|
  |
3DX7 | Crystal Structure of HLA-B*4403 presenting 10mer EBV antigen | C | A |
|
|
  |
3DX8 | Crystal Structure of B*4405 presenting a 10mer EBV epitope | C | A |
|
|
  |
3E7C | Glucocorticoid Receptor LBD bound to GSK866 | D | B |
|
|
  |
3E94 | Crystal structure of RXRalpha ligand binding domain in complex with tributyltin and a coactivator fragment | B | A |
|
|
  |
3EQS | Crystal structure of human MDM2 in complex with a 12-mer peptide inhibitor | B | A |
|
|
  |
3ET1 | Structure of PPARalpha with 3-[5-Methoxy-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-yl]-propionic acid | P | A |
|
|
  |
3ET3 | Structure of PPARgamma with 3-[5-Methoxy-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-yl]-propionic acid | P | A |
|
|
  |
3FQT | Phosphorylation of self-peptides alters Human Leukocyte Antigen Class I-restricted antigen presentation and generates tumor specific epitopes | C | A |
|
|
  |
3FQW | Phosphorylation of self-peptides alters Human Leukocyte Antigen Class I-restricted antigen presentation and generates tumor specific epitopes | C | A |
|
|
  |
3FUG | Crystal Structure of the Retinoid X Receptor Ligand Binding Domain Bound to the Synthetic Agonist 3-[4-Hydroxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-phenyl]acrylic Acid | B | A |
|
|
  |
3FXV | Identification of an N-oxide pyridine GW4064 analogue as a potent FXR agonist | B | A |
|
|
  |
3G03 | Structure of human MDM2 in complex with high affinity peptide | B | ACD |
|
|
  |
3G8I | Aleglitazar, a new, potent, and balanced PPAR alpha/gamma agonist for the treatment of type II diabetes | Z | A |
|
|
  |
3G9E | Aleglitaar. a new. potent, and balanced dual ppara/g agonist for the treatment of type II diabetes | B | A |
|
|
  |
3GIV | Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance | C | A |
|
|
  |
3GJF | Rational development of high-affinity T-cell receptor-like antibodies | C | LHA |
|
|
  |
3H0A | Crystal Structure of Peroxisome Proliferator-Activated Receptor Gamma (PPARg) and Retinoic Acid Receptor Alpha (RXRa) in Complex with 9-cis Retinoic Acid, Co-activator Peptide, and a Partial Agonist | B | A |
|
